In symptomatic patients with elevated pulmonary vascular resistance with normal pulmonary artery wedge pressure confirmed by right heart catheterization (similar to PAH pathophysiology), selective pulmonary vasodilator therapy (with epoprostenol or an endothelin-receptor antagonist) can be considered.